Filtered By:
Management: Marketing
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 20 results found since Jan 2013.
Bridging cancer biology and the patients' needs with nanotechnology-based approaches
Abstract: Cancer remains as stressful condition and a leading cause of death in the western world. Actual cornerstone treatments of cancer disease rest as an elusive alternative, offering limited efficacy with extensive secondary effects as a result of severe cytotoxic effects in healthy tissues. The advent of nanotechnology brought the promise to revolutionize many fields including oncology, proposing advanced systems for cancer treatment. Drug delivery systems rest among the most successful examples of nanotechnology. Throughout time they have been able to evolve as a function of an increased understanding from cancer bi...
Source: Cancer Treatment Reviews - March 10, 2014 Category: Cancer & Oncology Authors: Nuno A. Fonseca, Ana C. Gregório, Ângela Valério-Fernandes, Sérgio Simões, João N. Moreira Tags: Anti-Tumour Treatment Source Type: research
Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with Nitto Denko for Targeted siRNA Therapy in Advanced Non-alcoholic Steatohepatitis (NASH) and Cirrhosis Due to NASH
NEW YORK & OSAKA, Japan--(Healthcare Sales & Marketing Network)--Bristol-Myers Squibb Company (BMY) and Nitto Denko Corporation (Nitto) (6988:Tokyo) today announced the companies have entered into an agreement granting Bristol-Myers Squibb exclusive worldw... Biopharmaceuticals, Licensing Bristol-Myers Squibb, Nitto Denko
Source: HSMN NewsFeed - November 10, 2016 Category: Pharmaceuticals Source Type: news
Sirnaomics' Leading siRNA Therapeutic Candidate, STP705, Granted Orphan Designation for Treatment of Cholangiocarcinoma
GAITHERSBURG, Md., Dec. 6, 2017 -- (Healthcare Sales & Marketing Network) -- Sirnaomics, Inc. (www.sirnaomics.com), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the Office of Orphan Product De... Biopharmaceuticals, Oncology, FDA Sirnaomics, Cholangiocarcinoma
Source: HSMN NewsFeed - December 6, 2017 Category: Pharmaceuticals Source Type: news
Gene Therapy Leaves a Vicious Cycle
Reena Goswami1, Gayatri Subramanian2, Liliya Silayeva1, Isabelle Newkirk1, Deborah Doctor1, Karan Chawla2, Saurabh Chattopadhyay2, Dhyan Chandra3, Nageswararao Chilukuri1 and Venkaiah Betapudi1,4*
1Neuroscience Branch, Research Division, United States Army Medical Research Institute of Chemical Defense, Aberdeen, MD, United States
2Department of Medical Microbiology and Immunology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, United States
3Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States
4Department of Physiology and Biophysics, Case Western Reserve University, Clev...
Source: Frontiers in Oncology - April 23, 2019 Category: Cancer & Oncology Source Type: research
APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401
APEIRON to utilize MaxCyte's ExPERT® platform for siRNA-based cell therapy APN401 targeting solid tumors and secures manufacturing for upcoming clinical trials
VIENNA and GAITHERSBURG, Md., July 8, 2020 -- (Healthcare Sales & Marketing Network) -- ... Biopharmaceuticals, Oncology, Licensing MaxCyte, APEIRON Biologics, cell therapy
Source: HSMN NewsFeed - July 8, 2020 Category: Pharmaceuticals Source Type: news
Inclisiran in dyslipidemia
Drugs Today (Barc). 2021 May;57(5):311-319. doi: 10.1358/dot.2021.57.5.3277083.ABSTRACTCardiovascular disease (CVD) is the leading cause of death worldwide. Hypercholesterolemia has been shown to be one of the most important risk factors for CVD. Statins are currently the standard of care for the management of hypercholesterolemia. However, certain patients on statin therapy fail to achieve the desired low-density lipoprotein cholesterol (LDL-C) goals or are intolerant to statins due to side effects (mostly myalgias). The discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the subsequent development of P...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: C E Kosmas A Mu ñoz Estrella A Sourlas D Pantou Source Type: research
